Effect of Salbutamol on Walking Capacity in Ambulatory ALS Patients
Status:
Not yet recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
Preclinical and clinical data strongly suggest that administration of salbutamol in ALS
patients may improve walking capacity related to motor fatigue by enhancing neuromuscular
transmission. Salbutamol may exert a neuroprotective effect and slow down the progression of
clinical signs and symptoms. The main objective of the study is to test the efficacy of
salbutamol on walking capacity in ALS patients and the secondary objective is to measure the
target engagement of salbutamol on the neuromuscular junction (NMJ) at EMG (decrement of
repetitive nerve stimulation in three nerves/muscle couples), as well as safety and
tolerability. The exploratory objectives are to study the effect of salbutamol on fatigue
scales, muscle strength, respiratory function, motor unit count, muscle and spinal MRI
parameters and blood biomarkers